Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
NCT02137850
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
124
Enrollment
INDUSTRY
Sponsor class
Conditions
Congenital Bleeding Disorder
Haemophilia A
Interventions
DRUG:
turoctocog alfa pegol
Sponsor
Novo Nordisk A/S